Granted Patent
B2
US 12,279,825 · App. 18/243,869 · Granted Apr 22, 2025
Apparatus and methods to adjust ocular blood flow
Inventors:
John Berdahl (Sioux Falls, SD); George Tsai (Mission Viejo, CA); Hal Walbrink (Laguna Niguel, CA); Vance Michael Thompson (Sioux Falls, SD); Enrico Brambilla (Irvine, CA)
Assignee:
Balance Ophthalmics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
An apparatus to treat, inhibit, or prevent an eye condition in a patient can include a cover, sized and shaped to fit over an eye of a patient to define a cavity between the cover and an anterior surface of the eye when the cover is located over the patient eye. The apparatus can include a pressure source, in communication with the cavity, capable of applying non-ambient pressure in the cavity. The apparatus can include control circuitry, in communication with the pressure source, configured to vary non-ambient pressure applied to the cavity to affect a targeted pressure relationship between an indication of a first physiological pressure level and a second physiological pressure level associated with the eye of the patient.
Claims (33)
1. An apparatus to generate an indication of an ocular autoregulation (OA) index to characterize an autoregulation capability of an eye of a patient, the OA index characterized by at least two OA values, wherein an individual one of the at least two OA values includes an ordered pair relationship of an indication of ocular perfusion pressure (OPP) in the eye and an indication of blood flow in the eye, the apparatus comprising:
a cover, sized and shaped to fit over the eye to define a cavity between the cover and an anterior surface of the eye;
a pressure source, in communication with the cavity, configured to adjust fluid pressure in the cavity to affect the indication of OPP; and
control circuitry, in communication with the pressure source, the control circuitry configured to:
apply a first control signal to the pressure source to generate a first pressure in the cavity corresponding to a first indication of intraocular pressure (IOP) in the eye;
receive the first indication of IOP in the eye and a first indication of systemic blood pressure in the patient to calculate a first indication of OPP and a first indication of blood flow in the eye associated with the first indication of OPP to form a first OA value;
apply a second control signal to the pressure source to generate a different second pressure in the cavity corresponding to a second indication of IOP in the eye;
receive the second indication of IOP in the eye and a second indication of systemic blood pressure in the patient to calculate a second indication of OPP and a second indication of blood flow in the eye associated with the second indication of OPP to form a second OA value; and
calculate an OA index of the eye based upon the first OA value and the second OA value.
2. The apparatus of claim 1 , wherein an indication of OPP includes a difference between an indication of systemic blood pressure in the patient and an indication of intraocular pressure (IOP) in the eye.
3. The apparatus of claim 1 , wherein an indication of OPP includes a central tendency of OPP.
4. The apparatus of claim 1 , wherein an indication of blood flow in the eye includes an indication of blood flow sensed by an ocular blood flow sensor.
5. The apparatus of claim 4 , wherein the ocular blood flow sensor includes an ultrasonic sensor.
6. The apparatus of claim 4 , wherein the ocular blood flow sensor includes a charge coupled device (CCD).
7. The apparatus of claim 4 , wherein the ocular blood flow sensor includes a Doppler imaging system.
8. The apparatus of claim 4 , wherein the ocular blood flow sensor includes a laser speckle flowgraphy (LSF) system.
9. The apparatus of claim 4 , wherein the ocular blood flow sensor includes a laser speckle contrast imaging (LSCI) system.
10. The apparatus of claim 4 , wherein the ocular blood flow sensor includes a laser Doppler flowmeter (LDF).
11. The apparatus of claim 4 , wherein the ocular blood flow sensor includes an ocular coherence tomography angiography (ICTA) system.
12. The apparatus of claim 4 , wherein the ocular blood flow sensor includes a laser Doppler velocimetry (LDV) system.
13. The apparatus of claim 4 , wherein the ocular blood flow sensor includes a pattern electroretinography (PERG) test.
14. The apparatus of claim 1 , wherein the control circuitry is configured to determine an OA capability line that is characterized by at least two OA values, and wherein the OA index is determined using a slope of the OA capability line.
15. The apparatus of claim 1 , wherein the control circuitry is configured to determine an OA capability line that is characterized by at least two OA values, and wherein the OA index includes a length of the OA capability line.
16. A method of generating an indication of an ocular autoregulation (OA) index to characterize an autoregulation capability of an eye of a patient, the OA index characterized by at least two OA values, wherein an individual one of the at least two OA values includes an ordered pair relationship of an indication of ocular perfusion pressure (OPP) in the eye and an indication of blood flow in the eye, the method comprising:
applying a first cavity pressure in a cavity between a cover and an anterior surface of the eye to generate a first IOP;
measuring, at the first IOP, a first indication of OPP and a first indication of blood flow in the eye to form a first OA value;
applying a second cavity pressure in a cavity between a cover and an anterior surface of an eye to generate a second IOP;
measuring, at the second IOP, a second indication of OPP and a second indication of blood flow in the eye to form a second OA value; and
calculating an OA index based upon the first OA value and the second OA value.
17. The method of claim 16 , wherein measuring a first indication of OPP includes measuring a first indication of IOP from the eye and a first indication of systemic blood pressure in the patient at the first cavity pressure and wherein measuring a second indication of OPP includes measuring a second indication of IOP from the eye and a second indication of systemic blood pressure in the patient at the second cavity pressure.
18. The method of claim 17 , wherein measuring a first indication of OPP includes calculating the first indication of OPP from the measured first indication of IOP and the measured first indication of systemic blood pressure and wherein measuring a second indication of OPP includes calculating the second indication of OPP from the measured second indication of TOP and the second measured indication of systemic blood pressure.
19. The method of claim 16 , wherein calculating an OA index includes determining an OA capability line characterized by at least two OA values and determining the OA index from a slope of the OA capability line.
20. The method of claim 16 , wherein calculating an OA index includes determining a capability line characterized by at least two OA values and determining the OA index from a length of the capability line.
Assignments (2)
CHANGE OF NAME
Recorded Oct 3, 2023
From: EQUINOX OPHTHALMIC, INC.
To: BALANCE OPHTHALMICS, INC.
Reel/Frame 065102/0299 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 8, 2023
From: BERDAHL, JOHN; TSAI, GEORGE; WALBRINK, HAL; THOMPSON, VANCE MICHAEL; BRAMBILLA, ENRICO
To: EQUINOX OPHTHALMIC, INC.
Reel/Frame 064845/0647 →
Continuity (4)
Continuation
PCTUS2019045767
· Aug 8, 2019
Provisional Application
62716669
· Aug 9, 2018
References Cited (377)
US 2555636A
· Felts et al.
· 1951
[cited by applicant]
US 3545260A
· Lichtenstein et al.
· 1970
[cited by applicant]
US 4305399A
· Beale
· 1981
[cited by applicant]
US 4387707A
· Polikoff
· 1983
[cited by applicant]
US 4604087A
· Joseph et al.
· 1986
[cited by applicant]
US 4724843A
· Fisher
· 1988
[cited by applicant]
US 4907595A
· Strauss
· 1990
[cited by applicant]
US 5201312A
· Schenck et al.
· 1993
[cited by applicant]
US 5300020A
· L'Esperance, Jr.
· 1994
[cited by applicant]
US 5338291A
· Speckman et al.
· 1994
[cited by applicant]
US 5523808A
· Kohayakawa
· 1996
[cited by applicant]
US 5601548A
· Smith et al.
· 1997
[cited by applicant]
US 5625426A
· Liu
· 1997
[cited by applicant]
US 5927281A
· Monteleone et al.
· 1999
[cited by applicant]
US 5951477A
· Ragaluskals et al.
· 1999
[cited by applicant]
US 6093147A
· Kontiola
· 2000
[cited by applicant]
US 6129682A
· Borchert et al.
· 2000
[cited by applicant]
US 6307302B1
· Toda
· 2001
[cited by applicant]
US 6315727B1
· Coleman et al.
· 2001
[cited by applicant]
US 6673014B2
· Badchi et al.
· 2004
[cited by applicant]
US 6814966B1
· Wax et al.
· 2004
[cited by applicant]
US 7122007B2
· Querfurth
· 2006
[cited by applicant]
US 7137952B2
· Leonardi
· 2006
[cited by applicant]
US 7331666B2
· Swab et al.
· 2008
[cited by applicant]
US 7512436B2
· Petty et al.
· 2009
[cited by applicant]
US 7850638B2
· Theodore
· 2010
[cited by applicant]
US 8408204B2
· Lurie
· 2013
[cited by applicant]
US 8939906B2
· Huang et al.
· 2015
[cited by applicant]
US 8998810B2
· Kontiola et al.
· 2015
[cited by applicant]
US 9125724B2
· Berdahl et al.
· 2015
[cited by applicant]
US 9168172B1
· Berdahl
· 2015
[cited by applicant]
US 9173564B2
· Choo et al.
· 2015
[cited by applicant]
US 9498380B2
· Berdahl et al.
· 2016
[cited by applicant]
US 20020124843A1
· Skiba et al.
· 2002
[cited by applicant]
US 20020193675A1
· Rathjen
· 2002
[cited by applicant]
US 20030078486A1
· Klein et al.
· 2003
[cited by applicant]
US 20040111050A1
· Smedley et al.
· 2004
[cited by applicant]
US 20080171953A1
· Mische
· 2008
[cited by applicant]
US 20080306429A1
· Shields et al.
· 2008
[cited by applicant]
US 20090043365A1
· Friedland et al.
· 2009
[cited by applicant]
US 20090270711A1
· Jarvin et al.
· 2009
[cited by applicant]
US 20120222201A1
· Dondero
· 2012
[cited by applicant]
US 20130072828A1
· Sweis et al.
· 2013
[cited by applicant]
US 20130141690A1
· Taylor et al.
· 2013
[cited by applicant]
US 20130215376A1
· Guo et al.
· 2013
[cited by applicant]
US 20130218145A1
· Belkin et al.
· 2013
[cited by applicant]
US 20140378789A1
· McKinley et al.
· 2014
[cited by applicant]
US 20210068657A1
· Berdahl et al.
· 2021
[cited by applicant]
US 20230043903A1
· Berdahl et al.
· 2023
[cited by applicant]
AU 2016311449B2
· 2019
[cited by applicant]
AU 2019202196A1
· 2019
[cited by applicant]
AU 2019202196B2
· 2020
[cited by applicant]
AU 2022211909A1
· 2022
[cited by applicant]
AU 2022211909
· 2024
[cited by applicant]
CN 102264277A
· 2011
[cited by applicant]
CN 103479326A
· 2014
[cited by applicant]
CN 203989163U
· 2014
[cited by applicant]
CN 105764404
· 2016
[cited by applicant]
CN 108135738A
· 2018
[cited by applicant]
CN 113038869A
· 2021
[cited by applicant]
CN 113842266A
· 2021
[cited by applicant]
DE 19730735A1
· 1999
[cited by applicant]
IN 202117009018A
· 2021
[cited by applicant]
JP H03193037A
· 1991
[cited by applicant]
JP H11504537
· 1999
[cited by applicant]
JP H11326100
· 1999
[cited by applicant]
JP 2013255791A
· 2013
[cited by applicant]
JP 2018527143A
· 2018
[cited by applicant]
JP 2021180879A
· 2021
[cited by applicant]
JP 2021532920A
· 2021
[cited by applicant]
JP 2023021152A
· 2023
[cited by applicant]
KR 20180048749A
· 2018
[cited by applicant]
KR 102136640B1
· 2020
[cited by applicant]
WO WO2007012008A2
· 2007
[cited by applicant]
WO 2007018088
· 2007
[cited by applicant]
WO WO2007136993A1
· 2007
[cited by applicant]
WO WO2007139927A1
· 2007
[cited by applicant]
WO WO2010006180A1
· 2010
[cited by applicant]
WO WO2016071428A1
· 2016
[cited by applicant]
WO WO2017035406A2
· 2017
[cited by applicant]
WO WO2017035406A3
· 2017
[cited by applicant]
WO WO2017156050A1
· 2017
[cited by applicant]
WO WO2018174835A1
· 2018
[cited by applicant]
WO WO2020033736A1
· 2020
[cited by applicant]
WO WO2021053452A1
· 2021
[cited by applicant]
“European Application Serial No. 19759175.3, Indication of deficiencies in a request under Rule 22 EPC mailed Nov. 15, 2023”, 2 pgs.
[cited by applicant]
“U.S. Appl. No. 17/077,205, Non Final Office Action mailed Sep. 13, 2023”, 20 pgs.
[cited by applicant]
“Japanese Application Serial No. 2021-505948, Response filed Nov. 13, 2023 to Notification of Reasons for Rejection mailed Jun. 20, 2023”, w english claims, 10 pgs.
[cited by applicant]
“Australian Application Serial No. 2022211909, First Examination Report mailed Dec. 15, 2023”, 3 pgs.
[cited by applicant]
“Chinese Application Serial No. 201980065834.1, Office Action mailed Dec. 5, 2023”, w English Translation, 20 pgs.
[cited by applicant]
“Korean Application Serial No. 10-2024-7003071, Notice of Preliminary Rejection mailed Mar. 28, 2024”, w English translation, 10 pgs.
[cited by applicant]
U.S. Appl. No. 15/754,723 U.S. Pat. No. 10,842,376, filed Feb. 23, 2018, Eye-Related Intrabody Pressure Identification and Modification.
[cited by applicant]
U.S. Appl. No. 17/077,205, filed Oct. 22, 2020, Eye-Related Intrabody Pressure Identification and Modification.
[cited by applicant]
U.S. Appl. No. 17/168,670, filed Feb. 5, 2021, Apparatus and Methods to Adjust Ocular Blood Flow.
[cited by applicant]
“U.S. Appl. No. 12/380,239, Amendment filed May 8, 2014”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 12/380,239, Corrected Notice of Allowance mailed Jul. 8, 2015”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 12/380,239, Final Office Action mailed Oct. 8, 2014”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 12/380,239, Non Final Office Action mailed Feb. 6, 2015”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 12/380,239, Non Final Office Action mailed Jul. 14, 2011”, 15 pgs.
[cited by applicant]
“U.S. Appl. No. 12/380,239, Notice of Allowance mailed Jun. 19, 2015”, 5 pgs.
[cited by applicant]
“U.S. Appl. No. 12/380,239, Notice of Non-Compliant Amendment mailed Jun. 20, 2014”, 2 pgs.
[cited by applicant]
“U.S. Appl. No. 12/380,239, Response filed Jan. 7, 2015 to Final Office Action mailed Oct. 8, 2014”, 20 pgs.
[cited by applicant]
“U.S. Appl. No. 12/380,239, Response filed Apr. 16, 2014 to Non Final Office Action mailed Jul. 14, 2011”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 12/380,239, Response filed May 4, 2015 to Non Final Office Action mailed Feb. 6, 2015”, 13 pgs.
[cited by applicant]
“U.S. Appl. No. 12/380,239, Response filed Jul. 1, 2011 to Restriction Requirement mailed Jun. 2, 2011”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 12/380,239, Response filed Oct. 12, 2012 to Non Final Office Action mailed Jul. 14, 2011”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 12/380,239, Response to Notice of Non-Compliant Amendment mailed Jun. 24, 2014”, 14 pgs.
[cited by applicant]
“U.S. Appl. No. 12/380,239, Restriction Requirement mailed Jun. 2, 2011”, 5 pgs.
[cited by applicant]
“U.S. Appl. No. 13/790,048, Final Office Action mailed Feb. 5, 2015”, 13 pgs.
[cited by applicant]
“U.S. Appl. No. 13/790,048, Non Final Office Action mailed Jun. 24, 2014”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 13/790,048, Notice of Allowance mailed May 4, 2015”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 13/790,048, Response filed Apr. 2, 2015 to Final Office Action mailed Feb. 5, 2015”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 13/790,048, Response filed Sep. 24, 2014 to Non Final Office Action mailed Jun. 24, 2014”, 16 pgs.
[cited by applicant]
“U.S. Appl. No. 14/800,018, Examiner Interview Summary mailed Mar. 2, 2016”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 14/800,018, Non Final Office Action mailed Sep. 28, 2015”, 15 pgs.
[cited by applicant]
“U.S. Appl. No. 14/800,018, Notice of Allowance mailed Jul. 20, 2016”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 14/800,018, Preliminary Amendment filed Jul. 28, 2015”, 5 pgs.
[cited by applicant]
“U.S. Appl. No. 14/877,499, Non Final Office Action mailed Nov. 27, 2017”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 14/877,499, Notice of Allowance mailed Mar. 30, 2018”, 5 pgs.
[cited by applicant]
“U.S. Appl. No. 14/877,499, Preliminary Amendment filed Oct. 8, 2015”, 5 pgs.
[cited by applicant]
“U.S. Appl. No. 14/877,499, Response filed Feb. 14, 2018 to Non Final Office Action mailed Nov. 27, 2017”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Advisory Action mailed Jun. 14, 2022”, 5 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Advisory Action mailed Oct. 14, 2020”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Advisory Action mailed Dec. 2, 2019”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Corrected Notice of Allowability mailed Aug. 3, 2022”, 5 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Final Office Action mailed Mar. 30, 2022”, 17 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Final Office Action mailed Jul. 24, 2020”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Final Office Action mailed Aug. 22, 2019”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Non Final Office Action mailed Jan. 13, 2020”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Non Final Office Action mailed Feb. 15, 2019”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Non Final Office Action mailed May 25, 2021”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Notice of Allowance mailed Jul. 22, 2022”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Preliminary Amendment filed Nov. 16, 2016”, 5 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Response filed Apr. 13, 2020 to Non Final Office Action mailed Jan. 13, 2020”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Response filed May 31, 2022 to Final Office Action mailed Mar. 30, 2022”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Response filed Jun. 29, 2022 to Advisory Action mailed Jun. 14, 2022”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Response filed Sep. 23, 2020 to Final Office Action mailed Jul. 24, 2020”, 10 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Response filed Oct. 22, 2019 to Final Office Action mailed Aug. 22, 2019”, 10 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Response filed Nov. 22, 2021 to Non Final Office Action mailed May 25, 2021”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Response filed May 13, 2019 to Non Final Office Action mailed Feb. 15, 2019”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Response to Advisory Action mailed Jun. 14, 2022 & Final Office Action mailed Mar. 30, 2022”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 15/345,053, Supplemental Preliminary Amendment filed Aug. 21, 2017”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Advisory Action mailed Jul. 25, 2018”, 4 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Corrected Notice of Allowability mailed Jun. 15, 2020”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Examiner Interview Summary mailed Nov. 25, 2019”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Examiner Interview Summary mailed Dec. 31, 2018”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Final Office Action mailed Mar. 25, 2019”.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Final Office Action mailed May 15, 2018”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Non Final Office Action mailed Aug. 29, 2019”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Non Final Office Action mailed Oct. 5, 2018”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Non Final Office Action mailed Oct. 20, 2017”, 16 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Notice of Allowance mailed Feb. 20, 2020”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Preliminary Amendment filed Aug. 29, 2017”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Response filed Jan. 16, 2018 to Non Final Office Action mailed Oct. 20, 2017”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Response filed May 28, 2019 to Final Office Action mailed Mar. 25, 2019”, 10 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Response filed Jun. 12, 2018 to Final Office Action mailed May 15, 2018”, 10 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Response filed Aug. 15, 2018 to Advisory Action mailed Jul. 25, 2018”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Response filed Nov. 19, 2019 to Non Final Office Action mailed Aug. 29, 2019”, 10 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,016, Response filed Dec. 31, 2018 to Non Final Office Action mailed Oct. 5, 2018”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,043, Corrected Notice of Allowability mailed Sep. 13, 2018”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,043, Corrected Notice of Allowability mailed Sep. 28, 2018”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,043, Corrected Notice of Allowability mailed Nov. 20, 2018”, 2 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,043, Non Final Office Action mailed Mar. 15, 2018”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,043, Notice of Allowance mailed Jul. 16, 2018”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,043, Preliminary Amendment filed Aug. 29, 2017”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 15/688,043, Response filed Jun. 15, 2018 to Non Final Office Action mailed Mar. 15, 2018”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 15/754,723, Non Final Office Action mailed Apr. 17, 2020”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 15/754,723, Notice of Allowance mailed Jul. 29, 2020”, 5 pgs.
[cited by applicant]
“U.S. Appl. No. 15/754,723, Preliminary Amendment filed Feb. 23, 2018”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 15/754,723, Response filed Jul. 15, 2020 to Non Final Office Action mailed Apr. 17, 2020”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 15/754,723, Supplemental Notice of Allowability mailed Sep. 10, 2020”, 2 pgs.
[cited by applicant]
“U.S. Appl. No. 15/754,723, Supplemental Notice of Allowability mailed Oct. 21, 2020”, 2 pgs.
[cited by applicant]
“U.S. Appl. No. 15/754,723, Supplimental Preliminary Amendment filed Nov. 15, 2018”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, 312 Amendment filed Jan. 5, 2021”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Advisory Action mailed Mar. 11, 2020”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Corrected Notice of Allowability mailed Feb. 5, 2021”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Corrected Notice of Allowability mailed Feb. 12, 2021”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Examiner Interview Summary mailed Jul. 30, 2020”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Examiner Interview Summary mailed Aug. 30, 2019”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Final Office Action mailed Nov. 28, 2018”, 14 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Final Office Action mailed Dec. 12, 2019”, 13 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Non Final Office Action mailed Apr. 30, 2020”, 17 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Non Final Office Action mailed Jun. 6, 2019”, 13 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Non Final Office Action mailed Jun. 8, 2018”, 13 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Notice of Allowance mailed Oct. 5, 2020”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Response filed Jan. 4, 2019 to Final Office Action mailed Nov. 28, 2018”, 10 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Response filed Feb. 12, 2020 to Final Office Action mailed Dec. 12, 2019”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Response filed Mar. 20, 2020 to Advisory Action mailed Mar. 11, 2020”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Response filed Jul. 9, 2018 to Non Final Office Action mailed Jun. 8, 2018”, 15 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Response filed Jul. 30, 2020 to Non Final Office Action mailed Apr. 30, 2020”, 10 pgs.
[cited by applicant]
“U.S. Appl. No. 15/912,872, Response filed Sep. 6, 2019 to Non-Final Office Action mailed Jun. 6, 2019”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 17/077,205, Preliminary Amendment filed Nov. 25, 2020”, 6 pgs.
[cited by applicant]
“U.S. Appl. No. 17/142,304, Advisory Action mailed Nov. 23, 2021”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 17/142,304, Corrected Notice of Allowability mailed Oct. 3, 2022”, 4 pgs.
[cited by applicant]
“U.S. Appl. No. 17/142,304, Examiner Interview Summary mailed Apr. 19, 2022”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 17/142,304, Examiner Interview Summary mailed Dec. 16, 2021”, 2 pgs.
[cited by applicant]
“U.S. Appl. No. 17/142,304, Final Office Action mailed Aug. 13, 2021”, 10 pgs.
[cited by applicant]
“U.S. Appl. No. 17/142,304, Non Final Office Action mailed Jan. 20, 2022”, 13 pgs.
[cited by applicant]
“U.S. Appl. No. 17/142,304, Non Final Office Action mailed Mar. 16, 2021”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 17/142,304, Notice of Allowance mailed May 22, 2022”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 17/142,304, Notice of Allowance mailed May 25, 2022”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 17/142,304, Notice of Non-Compliant Amendment mailed Jun. 18, 2021”, 2 pgs.
[cited by applicant]
“U.S. Appl. No. 17/142,304, Response filed Apr. 19, 2022 to Non Final Office Action mailed Jan. 20, 2022”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 17/142,304, Response filed Jun. 14, 2021 to Non Final Office Action mailed Mar. 16, 2021”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 17/142,304, Response filed Jun. 28, 2021 to Notice of Non-Compliant Amendment mailed Jun. 18, 2021”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 17/142,304, Response filed Oct. 12, 2021 to Final Office Action mailed Aug. 13, 2021”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 17/168,670, 312 Amendment filed May 3, 2023”, 6 pgs.
[cited by applicant]
“U.S. Appl. No. 17/168,670, Corrected Notice of Allowability mailed Feb. 28, 2023”, 2 pgs.
[cited by applicant]
“U.S. Appl. No. 17/168,670, Corrected Notice of Allowability mailed Mar. 16, 2023”, 4 pgs.
[cited by applicant]
“U.S. Appl. No. 17/168,670, Corrected Notice of Allowability mailed Apr. 26, 2023”, 2 pgs.
[cited by applicant]
“U.S. Appl. No. 17/168,670, Non Final Office Action mailed Sep. 23, 2022”, 10 pgs.
[cited by applicant]
“U.S. Appl. No. 17/168,670, Notice of Allowance mailed Feb. 10, 2023”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 17/168,670, Preliminary Amendment filed Jun. 9, 2022”, 5 pgs.
[cited by applicant]
“U.S. Appl. No. 17/168,670, Response filed Dec. 22, 2022 to Non Final Office Action mailed Sep. 23, 2022”, 10 pgs.
[cited by applicant]
“U.S. Appl. No. 17/892,822, Preliminary Amendment filed Oct. 31, 2022”, 5 pgs.
[cited by applicant]
“U.S. Appl. No. 14/800,018 Response filed Jan. 15, 2016 to Non-Final Office Action mailed Sep. 28, 2015”, 20 pgs.
[cited by applicant]
“Australian Application Serial No. 2016311449, First Examination Report mailed Jul. 27, 2018”, 4 pgs.
[cited by applicant]
“Australian Application Serial No. 2019202196, First Examination Report mailed Apr. 22, 2020”, 5 pgs.
[cited by applicant]
“Australian Application Serial No. 2019202196, Response filed Aug. 19, 2020 to First Examination Report mailed Apr. 22, 2020”, 19 pgs.
[cited by applicant]
“Australian Application Serial No. 2019319942, First Examination Report mailed Aug. 9, 2021”, 3 pgs.
[cited by applicant]
“Australian Application Serial No. 2019319942, Response filed Apr. 22, 2022 to First Examination Report mailed Aug. 9, 2021”, 163 pgs.
[cited by applicant]
“Australian Application Serial No. 2020286245, First Examination Report mailed Apr. 8, 2022”, |4 pgs.
[cited by applicant]
“Biosensor”, Merriam-Webster dictionary, [Online]. Retrieved from the Internet: <https://www.merriam-webster.com/dictionary/biosensor>, (Jan. 6, 2020), 2 pgs.
[cited by applicant]
“Brazilian Application Serial No. 1120180038385, Office Action mailed Jun. 24, 2020”, w/ English Translation, 5 pgs.
[cited by applicant]
“Brazilian Application Serial No. 1120180038385, Response filed Oct. 5, 2020 to Office Action mailed Jun. 24, 2020”, w/ English Claims, 129 pgs.
[cited by applicant]
“Canadian Application Serial No. 2,998,477, Examiner's Rule 30(2) Requisition mailed Oct. 5, 2018”, 3 pgs.
[cited by applicant]
“Canadian Application Serial No. 2,998,477, Office Action mailed Feb. 17, 2020”, 6 pgs.
[cited by applicant]
“Canadian Application Serial No. 2,998,477, Office Action mailed Jun. 25, 2019”, 3 pgs.
[cited by applicant]
“Canadian Application Serial No. 2,998,477, Office Action mailed Aug. 7, 2020”, 6 pgs.
[cited by applicant]
“Canadian Application Serial No. 2,998,477, Response Filed Mar. 18, 2019 to Examiner's Rule 30(2) Requisition mailed Oct. 5, 2018”, 23 pgs.
[cited by applicant]
“Canadian Application Serial No. 2,998,477, Response filed Jun. 9, 2020 to Office Action mailed Feb. 17, 2020”, 18 pgs.
[cited by applicant]
“Canadian Application Serial No. 2,998,477, Response filed Nov. 9, 2020 to Office Action mailed Aug. 7, 2020”, 12 pgs.
[cited by applicant]
“Canadian Application Serial No. 2,998,477, Response filed Dec. 9, 2019 to Office Action mailed Jun. 25, 2019”, 19 pgs.
[cited by applicant]
“Canadian Application Serial No. 3,109,225, Examiner's Rule 86(2) Requisition Report mailed Sep. 8, 2022”, 3 pgs.
[cited by applicant]
“Canadian Application Serial No. 3,109,225, Office Action mailed Feb. 10, 2022”, 5 pgs.
[cited by applicant]
“Canadian Application Serial No. 3,109,225, Response filed Jan. 9, 2023 to Examiner's Rule 86(2) Requisition Report mailed Sep. 8, 2022”, 9 pgs.
[cited by applicant]
“Canadian Application Serial No. 3,109,225, Response Filed Jun. 10, 2022 to Office Action mailed Feb. 10, 2022”, 36 pgs.
[cited by applicant]
“Cataract Surgery to Lower Intraocular Pressure”, Middle East African Journal of Ophthalmology, 16 (3), (Sep. 2009), 1-5.
[cited by applicant]
“Chinese Application Serial No. 201680056279.2, Office Action mailed Feb. 19, 2021”, w/English Translation, 21 pgs.
[cited by applicant]
“Chinese Application Serial No. 201680056279.2, Office Action mailed May 22, 2020”, w/ English Translation, 19 pgs.
[cited by applicant]
“Chinese Application Serial No. 201680056279.2, Office Action mailed Sep. 12, 2019”, w/ English translation, 21 pgs.
[cited by applicant]
“Chinese Application Serial No. 201680056279.2, Response filed Jan. 16, 2020 to Office Action mailed Sep. 12, 2019”, w/ English Claims, 18 pgs.
[cited by applicant]
“Chinese Application Serial No. 201680056279.2, Response filed Jun. 7, 2021 to Office Action mailed Feb. 19, 2021”, w/ English claims, 28 pgs.
[cited by applicant]
“Chinese Application Serial No. 201680056279.2, Response filed Sep. 27, 2020 to Office Action mailed May 22, 2020”, w/ English Claims, 19 pgs.
[cited by applicant]
“Eurasian Application Serial No. 19759175.3, Response to Communication pursuant to Rules 161(1) and 162 EPC filed Sep. 13, 2021”, 16 pgs.
[cited by applicant]
“European Application Serial No. 16763632.3, Communication Pursuant to Article 94(3) EPC mailed Feb. 1, 2023”, 5 pgs.
[cited by applicant]
“European Application Serial No. 16763632.3, Communication Pursuant to Article 94(3) EPC mailed Mar. 26, 2020”, 4 pgs.
[cited by applicant]
“European Application Serial No. 16763632.3, Communication Pursuant to Article 94(3) EPC mailed Apr. 4, 2019”, 5 pgs.
[cited by applicant]
“European Application Serial No. 16763632.3, Communication Pursuant to Article 94(3) EPC mailed Jun. 17, 2021”, 4 pgs.
[cited by applicant]
“European Application Serial No. 16763632.3, Communication Pursuant to Article 94(3) EPC mailed Sep. 28, 2020”, 5 pgs.
[cited by applicant]
“European Application Serial No. 16763632.3, Communication Pursuant to Article 94(3) EPC mailed Oct. 18, 2019”, 4 pgs.
[cited by applicant]
“European Application Serial No. 16763632.3, Response filed Feb. 27, 2020 to Communication Pursuant to Article 94(3) EPC mailed Oct. 18, 2019”, 11 pgs.
[cited by applicant]
“European Application Serial No. 16763632.3, Response filed Apr. 8, 2021 to Communication Pursuant to Article 94(3) EPC mailed Sep. 28, 2020”, 19 pgs.
[cited by applicant]
“European Application Serial No. 16763632.3, Response filed Jul. 22, 2020 to Communication Pursuant to Article 94(3) EPC mailed Mar. 26, 2020”, 14 pgs.
[cited by applicant]
“European Application Serial No. 16763632.3, Response Filed Aug. 14, 2019 to Communication Pursuant to Article 94(3) EPC mailed Apr. 4, 2019”, 15 pgs.
[cited by applicant]
“European Application Serial No. 16763632.3, Response filed Nov. 1, 2018 to Communication Pursuant to Rules 161(1) and 162 EPC mailed Apr. 25, 2018”, w/ English Claims, 11 pgs.
[cited by applicant]
“European Application Serial No. 16763632.3, Response filed Dec. 27, 2021 to Communication Pursuant to Article 94(3) EPC mailed Jun. 17, 2021”, 14 pgs.
[cited by applicant]
“Eye-Related Intrabody Pressure Identification and Modification”, (Oct. 28, 2019), 3.
[cited by applicant]
“EyeGatell Transcription”, youtube, [Online]. Retrieved from the Internet: <URL: https://www.youtube.com/watch?v=v7oSLe-bLWo, (Accessed Nov. 3, 2017), 1 pg.
[cited by applicant]
“Indian Applicaiton Serial No. 201817010073, First Examination Report mailed Dec. 11, 2020”, w/ English Translation, 7 pgs.
[cited by applicant]
“Indian Applicaiton Serial No. 201817010073, Response filed Jun. 7, 2021 to First Examination Report mailed Dec. 11, 2020”, 138 pgs.
[cited by applicant]
“Indian Application Serial No. 202117009018, First Examination Report mailed Jan. 24, 2022”, 7 pgs.
[cited by applicant]
“Indian Application Serial No. 202117009018, Response filed Mar. 16, 2022 to First Examination Report mailed Jan. 24, 2022”, w/ English claims, 110 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2016/048784, International Preliminary Report on Patentability mailed Mar. 8, 2018”, 12 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2016/048784, International Search Report mailed Mar. 21, 2017”, 9 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2016/048784, Invitation to Pay Additional Fees and Partial Search Report mailed Nov. 28, 2016”, 7 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2016/048784, Written Opinion mailed Mar. 21, 2017”, 10 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2019/045767, International Preliminary Report on Patentability mailed Feb. 18, 2021”, 7 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2019/045767, International Search Report mailed Nov. 26, 2019”, 5 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2019/045767, Written Opinion mailed Nov. 26, 2019”, 7 pgs.
[cited by applicant]
“Japanese Application Serial No. 2018-529509, Examiners Decision of Final Refusal mailed Apr. 6, 2021”, w/ English Translation, 7 pgs.
[cited by applicant]
“Japanese Application Serial No. 2018-529509, Notification of Reasons for Refusal mailed Aug. 11, 2020”, w/ English translation, 9 pgs.
[cited by applicant]
“Japanese Application Serial No. 2018-529509, Notification of Reasons for Refusal mailed Dec. 15, 2020”, w/ English translation, 8 pgs.
[cited by applicant]
“Japanese Application Serial No. 2018-529509, Response filed Mar. 5, 21 to Notification of Reasons for Refusal mailed Dec. 15, 2020”, w/ English claims, 8 pgs.
[cited by applicant]
“Japanese Application Serial No. 2018-529509, Response filed Nov. 11, 2020 to Notification of Reasons for Refusal mailed Aug. 11, 2020”, w/ English Claims, 7 pgs.
[cited by applicant]
“Japanese Application Serial No. 2021-128035, Notification of Reasons for Rejection mailed Jul. 5, 2022”, w/ English Translation, 7 pgs.
[cited by applicant]
“Japanese Application Serial No. 2021-505948, Notification of Reasons for Refusal mailed May 10, 2022”, w/ English translation, 7 pgs.
[cited by applicant]
“Japanese Application Serial No. 2021-505948, Notification of Reasons for Refusal mailed Nov. 29, 2022”, w/ English translation, 11 pgs.
[cited by applicant]
“Japanese Application Serial No. 2021-505948, Response filed Feb. 2, 2023 to Notification of Reasons for Refusal mailed Nov. 29, 2022”, w/ English claims, 8 pgs.
[cited by applicant]
“Japanese Application Serial No. 2021-505948, Response filed Jul. 25, 2022 to Notification of Reasons for Refusal mailed May 10, 2022”, w/ English claims, 9 pgs.
[cited by applicant]
“Korean Application Serial No. 10-2018-7008191, Final Office Action mailed Jan. 23, 2020”, w/ English Translation, 5 pgs.
[cited by applicant]
“Korean Application Serial No. 10-2018-7008191, Notice of Preliminary Rejection mailed Jul. 10, 2019”, w/English Translation, 15 pgs.
[cited by applicant]
“Korean Application Serial No. 10-2018-7008191, Response filed Mar. 25, 2020 to Final Office Action mailed Jan. 23, 2020”, w/ English Claims, 12 pgs.
[cited by applicant]
“Korean Application Serial No. 10-2018-7008191, Response Filed Sep. 4, 2019 to Notice of Preliminary Rejection mailed Jul. 10, 2019”, w/English Claims, 26 pgs.
[cited by applicant]
“Korean Application Serial No. 10-2020-7020680, Final Office Action mailed Apr. 23, 2021”, w/English Translation, 10 pgs.
[cited by applicant]
“Korean Application Serial No. 10-2020-7020680, Notice of Preliminary Rejection mailed Oct. 5, 2020”, w/ English Translation, 9 pgs.
[cited by applicant]
“Korean Application Serial No. 10-2020-7020680, Response filed Jul. 22, 2021 to Final Office Action mailed Apr. 23, 2021”, w/ English claims, 12 pgs.
[cited by applicant]
“Korean Application Serial No. 10-2020-7020680, Response filed Dec. 7, 2020 to Notice of Preliminary Rejection mailed Oct. 5, 2020”, w/ English claims, 8 pgs.
[cited by applicant]
“Korean Application Serial No. 10-2021-7006949, Notice of Preliminary Rejection mailed Jan. 27, 2023”, w/ English Translation, 12 pgs.
[cited by applicant]
“Mexican Application Serial No. MX/a/2021/001497, Office Action mailed May 10, 2021”.
[cited by applicant]
Alexander, David J., et al., “Risk of Spaceflight-Induced Intracranial Hypertension and Vision Alterations”, Evidence Report—Version 1.0, (Jul. 12, 2012), 109 pgs.
[cited by applicant]
Allin, David, et al., “Laboratory Testing of the Pressio Intracranial Pressure Monitor”, Neurosurgery, vol. 62, vol. 5, [Online]. Retrieved from the Internet: <URL: www.neurosurgery-online.com, (May 2008), 1158-1161.
[cited by applicant]
Araci, Ismail E., et al., “An implantable microfluidic device for self-monitoring of intraocular pressure”, Nature Medicine, vol. 20, No. 9, (Sep. 2014), 1074-1080.
[cited by applicant]
Araci, Ismail E., “An implantable microfuidic device for self-monitoring of intraocular pressure”, nature medicine, vol. 20, No. 9—Technical Reports, (Sep. 2014), 1074-1080.
[cited by applicant]
Berdahl, et al., “Cerebrospinal fluid pressure is decreased in primary open-angle glaucoma”, Ophthalmology 115(5), (May 2008), 763-768.
[cited by applicant]
Berdahl, J. P., et al., “Intracranial pressure and glaucoma”, Curr Opin Ophthalmol (2), (Mar. 2010), 1 pg.
[cited by applicant]
Berdahl, J. P., et al., “The translaminar pressure gradient in sustained zero gravity, idiopathic intracranial hypertension, and glaucoma”, PubMed 79(6), (Dec. 2012), 1 pg.
[cited by applicant]
Berdahl, John P., et al., “Body Mass Index Has a Linear Relationship with Cerebrospinal Fluid Pressure”, IOVS, vol. 53, No. 3, (Mar. 2012), 1422-1427.
[cited by applicant]
Berdahl, John, “Cerebrospinal Fluid Pressure and Glaucoma”, Glaucoma Today, (Oct. 2009), 14-18.
[cited by applicant]
Berdahl, John P., et al., “Intracranial pressure and glaucoma”, Current Opinion in Ophthalmology 21-, (2010), 106-111.
[cited by applicant]
Berdahl, John P., et al., “Intracranial Pressure in Primary Open Angle Glaucoma, Normal Tension Glaucoma, and Ocluar Hypertension: A Case-Control Study”, IOVS, vol. 49, No. 12, (Dec. 2008), 5412-5418.
[cited by applicant]
Berdahl, John P., “Recovery of Corneal Hysteresis after Reduction of Intraocular Pressure in Chronic Primary Angle-Closure Glaucoma”, American Journal of Ophthalmology—Correspondence, (Oct. 2009), 623-624.
[cited by applicant]
Berdahl, John P., “Systemic Parameters Associated With Cerebrospinal Fluid Pressure”, J Glaucoma, vol. 22, No. 5, Suppl 1, [Online]. Retrieved from the Internet: <URL: www.glaucomajournal.com, (Jul. 2013), S17-S18.
[cited by applicant]
Berdahl, John P., “The translaminar pressure gradient in sustained zero gravity, idiopathic inracranial hypertension and glaucoma”, Medical Hypotheses 79, (2012), 719-724.
[cited by applicant]
Chowdhury, et al., “Intracranial Pressure and Its Relationship to Glaucoma: Current Understanding and Future Directions”, Med Hypothesis Discov Innov Ophthalmol, 4(3), (2015), 1 pg.
[cited by applicant]
Costa, Vital P., et al., “Ocular perfusion pressure in glaucoma”, Acta Ophthalmologica, (2014), e252-e266.
[cited by applicant]
Digre, Kathleen, “Not so benign intracranial hypertension”, MBJ, 326(7390), (Mar. 2, 20032), 4 pgs.
[cited by applicant]
Fleischman, David, et al., “Cerebrospinal Fluid Pressure Decreases with Older Age”, PLOS One, vol. 7, Issue 12, [Online]. Retrieved from the Internet: <URL: www.plosone.org, (Dec. 2012), 1-9.
[cited by applicant]
Fleischman, David, et al., “Increasing intraocular pressure as treatment for papilledema”, Experimental Eye Research 115, (2013), 278.
[cited by applicant]
Fleischman, David, et al., “The role of cerebrospinal fluid pressure in glaucoma and other ophthalmic diseases: A review”, Saudi Journal of Ophthalmology, 27, (2013), 97-106.
[cited by applicant]
Goel, Manik, et al., “Aqueous Humor Dynamics: A Review”, The Open Ophthalmology Journal, [Online]. Retrieved from the Internet: <URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3032230>, (2010), 52-59.
[cited by applicant]
Goldman, Robert M., et al., “The Effects of Oscillating Inversion on Systemic Blood Pressure, Pulse Intraocular Pressure, and Central Retinal Arterial Pressure”, The Physician and Sportsmedicine, vol. 13, No. 3, (Mar. 1…
[cited by applicant]
Hayreh, Sohan Singh, “Cerebrospinal fluid pressure and glaucomatous optic disc cupping (response to Berdahl and colleagues)”, Graefes Arch Clin Exp Opthtalmol, 247, (2009), 1291-1294.
[cited by applicant]
Hillen, Mark, “In Practice (VIIP: A Space Odyssey)”, The Ophthalmologist , vol. 11, (Sep. 2014), 6 pgs.
[cited by applicant]
Huberman, Andrew, “Managing Glaucoma: Beyond Intraocular Pressure. 2011”, Review of Opthalmology, [Online]. Retrieved from the Internet: <URL: : http://www.reviewofophthalmology.com/continuing_education/tabviewtest/less…
[cited by applicant]
Jacks, A. S., et al., “Spontaneous retinal venous pulsation: aetiology and significance”, J Neurol Neurosurg Psychiatry; 74, [Online]. Retrieved from the Internet: <URL: www.jnnp.com, (2002), 7-9.
[cited by applicant]
Jonas, Jost B., et al., “Anatomic Relationship between Lamina Cribosa, Intraocular Space, and Cerebrospinal Fluid Space”, Investigative Ophthalmology & Visual Science, vol. 44, No. 12, (Dec. 2003), 5189-5195.
[cited by applicant]
Jung, Jong Jin, et al., “Analysis of the Causes of Optic-Disc Swelling”, Korean J Ophthalmol, 25 (1), (2011), 33-36.
[cited by applicant]
Kent, Christopher, “IOP: Managing the Fluctuation Factor”, Review of Ophthalmology, [Online]. Retrieved from the Internet: <URL: http://www.reviewofophthalmology.com/content/i/1533/c/28662/dnnprintmode/true/?skinsrc=[I]…
[cited by applicant]
Kent, Christopher, “IOPP: Managing the Fluctuation Factor”, Review of Ophthamology, (Nov. 21, 2015), 6 pgs.
[cited by applicant]
Kwon, et al., “A Patient's Guide to Glaucoma”, sections 5A and 6B, (2006), 4 pgs.
[cited by applicant]
Lehman, et al., “Experimental effect of intracranial hypertension upon intraocular pressure”, J Neurosurg, 36(1):60-6, (Jan. 1972), 1 pg.
[cited by applicant]
Luo, et al., “Ocular blood flow autoregulation mechanisms and methods”, Eye Center, Renmin Hospital of Wuhan University, Wuhan, China; vol. 2015, (Oct. 21, 2015), 8 pgs.
[cited by applicant]
Morgan, William H., et al., “Retinal venous pulsation: Expanding our understanding and use of this enigmatic phenomenon”, Progress in Retinal and Eye Research xxx, (2016), 1-26.
[cited by applicant]
Morgan, William H, et al., “The Correlation between Cerebrospinal Fluid Pressure and Retrolaminar Tissue Pressure”, IOVS, Jul. 1998, vol. 39, No. 8, (Jul. 1998), 10 pgs.
[cited by applicant]
Muenster, Stefan, et al., “The Ability of Nitric Oxide to Lower Intraocular Pressure Is Dependent on Guanylyl Cyclase”, Investigative Ophthalmology & Visual Science, vol. 58, No. 11, (Sep. 2017), 4826-4835.
[cited by applicant]
Parsa, C F, “Spontaneous venous pulsations should be monitored during glaucoma therapy”, Br J Ophthalmol, 86(10), (Oct. 2002), 1187.
[cited by applicant]
Sajjadi, et al., “The Relation between Intracranial and Intraocular Pressures: Study of 50 Patients”, Ann Neurol, (2006), 867-870.
[cited by applicant]
Samuelson, T W, “Intracranial pressure may play significant role in glaucoma”, Ocular Surgery News US Edition, (Oct. 25, 2008), 3 pgs.
[cited by applicant]
Siaudvytyte, Lina, et al., “Update in intracranial pressure evaluation methods and translaminar pressure gradient role in glaucoma”, ACTA Opththmalologica, 93, (2015), 9-15.
[cited by applicant]
Wostyn, Peter, et al., “Glaucoma and the Role of Cerebrospinal Fluid Dynamics”, Investigative Ophthalmology & Visual Sciences, (2015), 6630.
[cited by applicant]
Wuthrich, U. W., “Postural change and intraocular pressure in glaucomatous eyes”, Brit. J. Ophthal. 60, (1976), 111-114.
[cited by applicant]
Xie, Xiaobin, et al., “Noninvasive intracranial pressure estimation by orbital subarachnoid space measurement: the Beijing Intracranial and Intraocular Pressure (iCOP) study”, Critical Care, 17:R162, [Online]. Retrieved…
[cited by applicant]
Yeoh, Ronald, “Hydrorupture of the posterior capsule in femtosecond-laser cataract surgery”, J Cataract Refract Surg, vol. 38, (Apr. 2012), 730-731.
[cited by applicant]
Young, Joshua, “ASFH CSF Pressure and Glaucoma (Guest: John P. Berdahl, M.D.)”, As Seen From Here: 198 (Podcast—iTunes) (Transcribed) Run time: 15:14 Minutes, (Jul. 8, 2008), 5 pgs.
[cited by applicant]
Zhang, Zheng, et al., “Glaucoma and the Role of Cerebrospinal Fluid Dynamics”, Investigative Ophthalmology & Visual Sciences, (2015), 6632.
[cited by applicant]
“Australian Application Serial No. 2024227715, Voluntary Amendment filed Jan. 3, 2025”, 6 pgs.
[cited by applicant]
“Application Serial No. 18 538,603, Non Final Office Action mailed Feb. 18, 2025”, 14 pgs.
[cited by applicant]
“Mexican Application Serial No. MX a 2021 001497, Response filed Oct. 10, 2024 to Office Action mailed Jun. 25, 2024”, W English Claims, 14 pgs.
[cited by applicant]